Role of plasmalogens in the enhanced resistance of LDL to copper-induced oxidation after LDL apheresis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 10, 1999, Pages 2431-2438

  Hahnel, Daniela ^a   Thiery, Joachim ^b   Brosche, Thorolf ^c   Engelmann, Bernd ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Lag times; LDL apheresis; LDL oxidation; Lysophosphatidylcholine; Plasmalogen phospholipids

Indexed keywords

ALPHA TOCOPHEROL; BETA CAROTENE; COPPER; LOW DENSITY LIPOPROTEIN; LYSOPHOSPHATIDYLCHOLINE; MONOUNSATURATED FATTY ACID; PHOSPHATIDYLCHOLINE; PLASMALOGEN; POLYUNSATURATED FATTY ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; LIPID COMPOSITION; LIPID OXIDATION; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN STABILITY; REACTION TIME; TREATMENT OUTCOME;

EID: 0032849731     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.10.2431     Document Type: Article

References (53)

1. Steinberg D. Conner memorial lecture: oxidative modifications of LDL and atherogenesis. Circulation. 1997;95:1062-1071.
2. Holvoet P, Collen D. Thrombosis and atherosclerosis. Curr Opin Lipidol. 1997;8:320-328.
3. Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified lipoproteins: a potential role in recruitment and retention of monocyte/ macrophages during atherogenesis. Proc Natl Acad Sci U S A. 1987;84: 2995-2998.
4. Fogelman AM, Shechter J, Seager J, Hokom M, Child JS, Edwards PA. Malondialdehyde alteration of low density lipoprotein leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc Natl Acad Sci U S A. 1980;77:2214-2218.
5. Galle J, Bassenge R, Busse R. Oxidized low density lipoproteins potentiate vasoconstrictions to various agonists by direct interaction with vascular smooth muscle. Circ Res. 1990;66:1287-1293.
6. Palinski W, Rosenfeld ME, Ylä-Herttuala S, Gurtner GC, Socher SS, Butler SW, Parthasarathy S, Carew TE, Steinberg D, Witztum JL. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci U S A. 1989;86:1372-1376.
7. Regnström J, Nilsson J, Per Tornvall CL, Hamsten A. Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man. Lancet. 1992;339:1183-1186.
8. Chiu HC, Jeng JR, Shieh SM. Increased oxidizability of plasma low density lipoprotein from patients with coronary artery disease. Biochim Biophys Acta. 1994;1225:200-208.
9. Halevy D, Thiery J, Nagel D, Arnold S, Erdmann E, Höfling B, Cremer P, Seidel D. Increased oxidation of LDL in patients with coronary artery disease is independent from dietary vitamins E and C. Arterioscler Thromb Vasc Biol. 1997;17:1432-1437.
10. Gordon BR, Saal SD. Current status of low density lipoprotein apheresis for the therapy of severe hyperlipidemia. Curr Opin Lipidol. 1996;7: 381-384.
11. Gordon BR, Kelsey SF, Dau PC, Gotto AM Jr, Graham K, Illingworth DR, Isaacsohn J, Jones PH, Leitman SF, Saal SD, Stern TN, Troendle A, Zwiener RJ. Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system: Liposorber Study Group. Am J Cardiol. 1998;81:407-411.
12. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation. 1997;95:76-82.
13. Cattin L, Petrucco A, Cazzolato G, Bon GB, Borelli V, Nardon E, Zabucchi G, Fonda M, Bordin P. Low density lipoprotein apheresis decreases oxidized low density lipoproteins and monocyte adhesion to endothelial cells. ASAIO J. 1997;43:209-213.
14. Sampietro T, Tuoni M, Ferdeghini M, Ciardi A, Marraccini P, Prontera C, Sassi G, Taddei M, Bionda A. Plasma cholesterol regulates soluble cell adhesion molecule expression in familial hypercholesterolemia. Circulation. 1997;96:1381-1385.
15. Leitinger N, Pirich C, Blazek I, Endler G, Sinzinger H. Decreased susceptibility of low-density lipoproteins to in vitro-oxidation after dextransulfate LDL apheresis treatment. Atherosclerosis. 1996;25:305-312.
16. Napoli C, Ambrosio G, Scarpato N, Corso G, Palumbo G, D'Armiento FP, Mancini FP, Malorini A, Formisano S, Ruocco A, Cali A, Chiariello M. Decreased low-density lipoprotein oxidation after repeated selective apheresis in homozygous familial hypercholesterolemia. Am Heart J. 1997;133:585-595.
17. Bowry VW, Ingold KU, Stocker R. Vitamin E in human low-density lipoprotein: when and how this antioxidant becomes a pro-oxidant. Biochem J. 1992;288:341-344.
18. Kontush A, Finckh B, Karten B, Kohlschütter A, Beisiegel U. Antioxidant and prooxidant activity of α-tocopherol in human plasma and low density lipoprotein. J Lipid Res. 1996;37:1436-1448.
19. Ziouzenkova O, Gieseg SP, Ramos P, Esterbauer H. Factors affecting resistance of low density lipoproteins to oxidation. Lipids. 1996; 31(suppl):S-71-S-76.
20. Bonanome A., Pagnan A, Biffanti S, Opportuno A, Sorgato F, Dorella M, Maiorino M, Ursini F. Effect of monounsaturated and polyunsaturated fatty acids on the susceptibility of plasma low density lipoproteins to oxidative modification. Arterioscler Thromb Vasc Biol. 1992;12: 529-533.
21. Jialal I, Norkus EP, Cristol L, Grundy SM. Carotene inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta. 1991; 1086:134-138.
22. Stocker R, Bowry VW, Frei B. Ubiquinol-10 protects low density lipoprotein more efficiently against lipid peroxidation than does α-tocopherol. Proc Natl Acad Sci U S A. 1991;88:1646-1650.
23. Kontush A, Hübner C, Finckh B, Kohlschütter A, Beisiegel U. Low density lipoprotein oxidizability by copper correlates to its initial ubiquinol-10 and polyunsaturated fatty acid content. FEBS Lett. 1994; 341:69-73.
24. Engelmann B, Bräutigam C, Thiery J. Plasmalogen phospholipids as potential protectors against lipid peroxidation of low density lipoproteins. Biochem Biophys Res Commun. 1994;204:1235-1242.
25. Jürgens G, Fell A, Chen Q, Paltauf F. Delay of copper-catalyzed oxidation of low density lipoprotein by in vitro enrichment with choline or ethanolamine plasmalogen. Chem Phys Lipids. 1995;77:25-31.
26. Thiery J, Seidel D. LDL apheresis: clinical experience and indications in the treatment of severe hypercholesterolemia. Transfus Sci. 1993;14: 249-255.
27. Wallin B, Rosengren B, Shertzer HG, Camejo G. Lipoprotein oxidation and measurement of thiobarbituric acid reacting substances formation in a single microtiter plate: its use for evaluation of antioxidants. Anal Biochem. 1993;208:10-15.
28. Thiery J, Teupser D, Walli AK, Ivandic B, Nebendahl K, Setin O, Stein Y, Seidel D. Study of causes underlying the low atherosclerotic response to dietary hypercholesterolemia in a selected strain of rabbits. Atherosclerosis. 1996;121:63-73.
29. Hess D, Keller HE, Oberlin B, Bonfanti R, Schüepp W. Simultaneous determination of retinol, tocopherols, carotenes, and lycopene in plasma by means of high-performance liquid chromatography on reversed phase. Int J Vit Nutr Res. 1991;61:232-238.
30. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:912-917.
31. Broekhuyse RM. Quantitative two dimensional thin-layer chromatography of blood phospholipids. Clin Chim Acta. 1969;23:457-461.
32. Engelmann B, Streich S, Schönthier UM, Richter WO, Duhm J. Changes of membrane phospholipid composition of human erythrocytes in hyperlipidemias, I: increased phosphatidylcholine and reduced sphingomyelin in patients with elevated levels of triacylglycerol-rich lipoproteins. Biochim Biophys Acta. 1992;1165:32-37.
33. Morrison WR, Smith IM. Preparation of fatty acid methylesters and dimethylacetals from lipids with boron-trifluoride methanol. J Lipid Res. 1964;5:600-608.
34. Reiss D, Beyer K, Engelmann B. Delayed oxidative degradation of polyunsaturated diacyl phospholipids in the presence of plasmalogen phospholipids in vitro. Biochem J. 1997;323:807-814.
35. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955;34:1345-1353.
36. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
37. Richter WO, Jacob BG, Ritter MM, Sühler K, Vierneisel K, Schwandt P. Three-year treatment of familial heterozygous hypercholesterolemia by extracorporal low-density-lipoprotein immunoadsorption with polyclonal apolipoprotein B antibodies. Metabolism. 1993;42:888-894.
38. Quinn MT, Parthasarathy S, Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci U S A. 1988;85:2805-2809.
39. Meyer DF, Nealis AS, Macphee CH, Groot PH, Suckling KE, Bruckdorfer KR, Perkins SJ. Time-course studies by synchrotron X-ray solution scattering of the structure of human low-density lipoprotein during Cu(2+)-induced oxidation in relation to changes in lipoprotein composition. Biochem J. 1996;319:217-227.
40. Neuzil J, Thomas SR, Stocker R. Requirement for, promotion, or inhibition by α-tocopherol of radical-induced initiation of plasma lipoprotein lipid peroxidation. Free Radic Biol Med. 1997;22:57-71.
41. Ylä-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinherg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989;84:1086-1095.
42. Smith C, Mitchinson MJ, Aruoma OI, Halliwell B. Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions. Biochem J. 1992;286:901-905.
43. Mukhopadhyay CK, Mazumder B, Lindley PF, Fox, PL. Identification of the prooxidant site of human ceruloplasmin: a model for oxidative damage by copper bound to protein surfaces. Proc Natl Acad Sci U S A. 1997;94:11546-11551.
44. Heinecke JW. Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidixed low density lipoprotein hypothesis. Atherosclerosis. 1998;141:1-15.
45. Zoeller RA, Morand OH, Raetz CRH. A possible role for plasmalogens in protecting animal cells against photosensitized killing. J Biol Chem. 1988;263:11590-11596.
46. Zommara M, Tachibana N, Mitsui K, Nakatani N, Sakono M, Ikeda I, Imaizumi K. Inhibitory effect of ethanolamine plasmalogen on iron- and copper-dependent lipid peroxidation. Free Radic Biol Med. 1995;18: 599-602.
47. Frei B, Gaziano JM. Content of antioxidants, preformed lipid hydroperoxides, and cholesterol as predictors of the susceptibility of human LDL to metal ion-dependent and -independent oxidation. J Lipid Res. 1993; 34:2135-2145.
48. Engelmann B, Bräutigam C, Kulschar R, Duhm J, Prenner E, Hermetter A, Richter WO, Thiery J, Seidel D. Reversible reduction of phospholipid bound arachidonic acid after low density lipoprotein apheresis: evidence for rapid incorporation of plasmalogen phosphatidylethanolamine into the red blood cell membrane. Biochim Biophys Acta. 1994;1196:154-164.
49. Bräutigam C, Engelmann B, Reiss D, Reinhardt U, Thiery J, Richter WO, Brosche T. Plasmalogen phospholipids in plasma lipoproteins of normolipidemic donors and patients with hypercholesterolemia treated by LDL apheresis. Atherosclerosis. 1996;119:77-88.
50. Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry P. Impairment of endothelial-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature. 1990;344:160-162.
51. Kume N, Gimbrone MA Jr. Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J Clin Invest. 1994;93:907-911.
52. Stadler RW, Ibrahim SF, Lees RS. Peripheral vasoactivity in familial hypercholesterolemic subjects treated with heparin-induced extracorporal LDL precipitation (HELP). Atherosclerosis. 1997;128:241-249.
53. Mellwig KP, Baller D, Gleichmann U, Moll D, Betker S, Weise R, Notohamiprodjo G. Improvement of coronary vasodilation capacity through single LDL apheresis. Atherosclerosis. 1998;139:173-178.